Overview

Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2DM)

Status:
Recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
A Phase 1/ 2 Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMF-219, an Oral Covalent Menin Inhibitor, in Healthy Adult Subjects and in Adult Subjects with Type 2 Diabetes Mellitus.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Biomea Fusion Inc.